Table 3

Estrogen receptor (ER) and HER2 status in breast cancers of all patients (Sulaimaniyah Kurds, non-Sulaimaniyah Kurds and Arabs) having immunohistochemistry studies
Characteristic ER+/HER2- ER+/HER2+ ER-/HER2- ER-/HER2+ Triple negative P value*
No. % No. % No. % No. % No. %
age 0.12
20-49 154 59.9 31 12.1 36 14.0 36 14.0 30 11.7
50-59 71 69.6 5 4.9 14 13.7 12 11.8 12 11.8
≥ 60 54 78.3 5 7.2 5 7.2 5 7.2 5 7.2
Stage 0.81
1 24 64.9 5 13.5 6 16.2 2 5.4 4 10.8
2 92 68.1 10 7.4 17 12.6 16 11.9 13 9.6
3 73 63.5 12 10.4 13 11.3 17 14.8 13 11.3
4 16 57.1 5 17.9 5 17.9 2 7.1 4 14.3
Grade <0.001
I 43 97.7 0 0 1 2.3 0 0 1 2.3
II 157 80.9 12 6.2 11 5.7 14 7.2 8 4.1
III 65 40.6 22 13.8 38 23.8 35 21.9 33 20.6

* Comparing the distribution of ER/HER2 status and triple negative tumors by patient age, tumor stage, and tumor grade (X2 tests).

Tumor characteristics are compared by age, tumor stage, and tumor grade.

Majid et al.

Majid et al. BMC Women's Health 2012 12:16   doi:10.1186/1472-6874-12-16

Open Data